Investors

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that the Company has issued 358,772 options over new ordinary shares with an exercise price of 11 pence per share (“New Options”) to Sofia Kolyda, a Director of the Company.

The New Options expire on 6 August 2035 with 269,079 of the New Options vesting on the first anniversary of the options being granted being 6 August 2026 and the balance (comprising 89,693 New Options) vesting once the Company signs a commercial agreement with a partner providing equal or greater than £100k revenues per annum for products containing SweetBiotix.

The issue of the New Options follows the expiration of 358,772 options of ordinary shares granted to Sofia Kolyda which expired in March 2025 of which 75% had vested.

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

For further information, please contact:

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.